UK-based footwear retailer Dr. Martens reported a weak performance for the first quarter of 2025, with revenue dropping by 10% to around $1.1 billion.
The brand’s revenue in America plunged by 11%, and it also saw its revenue drop by 11% in the Europe, Middle East, and Africa region.
During the first quarter, the company achieved its goal of bringing the direct-to-consumer channel in America into profitability.
Ije Nwokorie, CEO of Dr. Martens, said:”Our single focus in FY25 was to bring stability back to Dr. Martens. We have achieved this by returning our direct-to-consumer channel in the Americas back to growth, resetting our marketing approach to focus relentlessly on our products, delivering cost savings, and significantly strengthening our balance sheet.”
Moving forward, the footwear giant plans to execute a business strategy that will focus on consumers to drive a turnaround in its overall performance.
As part of its strategy, Dr. Martens plans to strengthen customer engagement, bring out more product purchase events, develop its marketing distribution, and streamline its operations.
The footwear giant said it will be keeping the prices of its products unchanged in America in the meantime despite the additional tariffs.
Meanwhile, other footwear retailers in the US have been struggling due to the additional headwinds from tariffs.
Designer Brands recently reported declining sales and swung to a loss in Q1 2025, while popular footwear brand Crocs had mixed results in its first quarter and withdrew its guidance.
Click here to sign up to Retail Gazette‘s free daily email newsletter
